Article Review: Cancer control outcomes of Radium 223 pretreated lutetium 177 PSMA Radioligand vs Radium 223 na ve mCRPC patients

Objectives This study investigated the cancer-control outcomes of Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA) in metastatic castration-resistant prostate cancer (mCRPC) patients who were either pretreated with Ra...